Our top pick for
Building a portfolio
ASLAN Pharmaceuticals Limited is a biotechnology business based in the US. ASLAN Pharmaceuticals shares (ASLN) are listed on the NASDAQ and all prices are listed in US Dollars.
|52-week range||USD$0.8707 - USD$6.75|
|50-day moving average||USD$3.5085|
|200-day moving average||USD$2.2397|
|Wall St. target price||USD$8.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.045|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$79.8 million|
|Return on assets TTM||-49.34%|
|Return on equity TTM||-5313.82%|
|Market capitalisation||USD$250.6 million|
TTM: trailing 12 months
There are currently 8,711 ASLAN Pharmaceuticals shares held short by investors – that's known as ASLAN Pharmaceuticals's "short interest". This figure is 47.7% down from 16,643 last month.
There are a few different ways that this level of interest in shorting ASLAN Pharmaceuticals shares can be evaluated.
ASLAN Pharmaceuticals's "short interest ratio" (SIR) is the quantity of ASLAN Pharmaceuticals shares currently shorted divided by the average quantity of ASLAN Pharmaceuticals shares traded daily (recently around 871100). ASLAN Pharmaceuticals's SIR currently stands at 0.01. In other words for every 100,000 ASLAN Pharmaceuticals shares traded daily on the market, roughly 10 shares are currently held short.
However ASLAN Pharmaceuticals's short interest can also be evaluated against the total number of ASLAN Pharmaceuticals shares, or, against the total number of tradable ASLAN Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ASLAN Pharmaceuticals's short interest could be expressed as 0% of the outstanding shares (for every 100,000 ASLAN Pharmaceuticals shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable ASLAN Pharmaceuticals shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ASLAN Pharmaceuticals.
Find out more about how you can short ASLAN Pharmaceuticals stock.
We're not expecting ASLAN Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, ASLAN Pharmaceuticals's shares have ranged in value from as little as $0.8707 up to $6.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ASLAN Pharmaceuticals's is 2.5614. This would suggest that ASLAN Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
ASLAN Pharmaceuticals Limited, a clinical-stage immunology and oncology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and a small molecule inhibitor targeting oncology. Its partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore. .
Everything we know about the Vaccitech IPO, plus information on how to buy in.
Everything we know about the Artiva Biotherapeutics IPO, plus information on how to buy in.
Everything we know about the Five Star Bancorp IPO, plus information on how to buy in.
Everything we know about the Twin Vee PowerCats IPO, plus information on how to buy in.
Everything we know about the Werewolf Therapeutics IPO, plus information on how to buy in.
Everything we know about the Onion Global Limited IPO, plus information on how to buy in.
Everything we know about the Orbsat Corp IPO, plus information on how to buy in.
Everything we know about the Splash Beverage Group IPO, plus information on how to buy in.
Everything we know about the Privia Health Group IPO, plus information on how to buy in.
Everything we know about the Bowman Consulting Group Ltd IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.